552 related articles for article (PubMed ID: 14631615)
21. Changes of hemostatic factors in patients with hemoglobinopathies.
Oner AF; Gürgey A; Okur H; Kirazli S; Gümrük F; Altay C
Turk J Pediatr; 1999; 41(3):323-7. PubMed ID: 10770092
[TBL] [Abstract][Full Text] [Related]
22. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia.
Karimi M; Mohammadi F; Behmanesh F; Samani SM; Borzouee M; Amoozgar H; Haghpanah S
Eur J Haematol; 2010 Jan; 84(1):52-8. PubMed ID: 19799627
[TBL] [Abstract][Full Text] [Related]
23. Hydroxyurea in the treatment of major beta-thalassemia and importance of genetic screening.
Alebouyeh M; Moussavi F; Haddad-Deylami H; Vossough P
Ann Hematol; 2004 Jul; 83(7):430-3. PubMed ID: 14722738
[TBL] [Abstract][Full Text] [Related]
24. Enhanced thrombin generation in children with sickle cell disease.
Peters M; Plaat BE; ten Cate H; Wolters HJ; Weening RS; Brandjes DP
Thromb Haemost; 1994 Feb; 71(2):169-72. PubMed ID: 8191393
[TBL] [Abstract][Full Text] [Related]
25. Response to hydroxyurea in beta thalassemia major and intermedia: experience in western India.
Italia KY; Jijina FJ; Merchant R; Panjwani S; Nadkarni AH; Sawant PM; Nair SB; Ghosh K; Colah RB
Clin Chim Acta; 2009 Sep; 407(1-2):10-5. PubMed ID: 19545554
[TBL] [Abstract][Full Text] [Related]
26. Clinical response and adverse events in young patients with sickle cell disease treated with hydroxyurea.
Kattamis A; Lagona E; Orfanou I; Psichou F; Ladis V; Kanavakis E; Metaxotou-Mavrommati A; Kattamis C
Pediatr Hematol Oncol; 2004 Jun; 21(4):335-42. PubMed ID: 15205096
[TBL] [Abstract][Full Text] [Related]
27. Hydroxyurea in children: present and future.
Vichinsky EP
Semin Hematol; 1997 Jul; 34(3 Suppl 3):22-9. PubMed ID: 9317198
[TBL] [Abstract][Full Text] [Related]
28. KLF10 gene expression is associated with high fetal hemoglobin levels and with response to hydroxyurea treatment in β-hemoglobinopathy patients.
Borg J; Phylactides M; Bartsakoulia M; Tafrali C; Lederer C; Felice AE; Papachatzopoulou A; Kourakli A; Stavrou EF; Christou S; Hou J; Karkabouna S; Lappa-Manakou C; Ozgur Z; van Ijcken W; von Lindern M; Grosveld FG; Georgitsi M; Kleanthous M; Philipsen S; Patrinos GP
Pharmacogenomics; 2012 Oct; 13(13):1487-500. PubMed ID: 23057549
[TBL] [Abstract][Full Text] [Related]
29. Hydroxyurea therapy lowers TCD velocities in children with sickle cell disease.
Kratovil T; Bulas D; Driscoll MC; Speller-Brown B; McCarter R; Minniti CP
Pediatr Blood Cancer; 2006 Dec; 47(7):894-900. PubMed ID: 16526051
[TBL] [Abstract][Full Text] [Related]
30. Effects of hydroxyurea on the membrane of erythrocytes and platelets in sickle cell anemia.
Covas DT; de Lucena Angulo I; Vianna Bonini Palma P; Zago MA
Haematologica; 2004 Mar; 89(3):273-80. PubMed ID: 15020264
[TBL] [Abstract][Full Text] [Related]
31. Response to hydroxyurea therapy in beta-thalassemia.
Koren A; Levin C; Dgany O; Kransnov T; Elhasid R; Zalman L; Palmor H; Tamary H
Am J Hematol; 2008 May; 83(5):366-70. PubMed ID: 18181203
[TBL] [Abstract][Full Text] [Related]
32. Hydroxyurea in thalassemia intermedia--a promising therapy.
Dixit A; Chatterjee TC; Mishra P; Choudhry DR; Mahapatra M; Tyagi S; Kabra M; Saxena R; Choudhry VP
Ann Hematol; 2005 Jul; 84(7):441-6. PubMed ID: 15838670
[TBL] [Abstract][Full Text] [Related]
33. Increased erythropoietin level induced by hydroxyurea treatment of sickle cell patients.
Papassotiriou I; Voskaridou E; Stamoulakatou A; Loukopoulos D
Hematol J; 2000; 1(5):295-300. PubMed ID: 11920206
[TBL] [Abstract][Full Text] [Related]
34. [Effect of hydroxyurea on hemoglobin S].
Torres AF; Eberle SE; Sciuccati G; Bonduel M
Medicina (B Aires); 2003; 63(2):140-2. PubMed ID: 12793083
[TBL] [Abstract][Full Text] [Related]
35. Use of hydroxyurea in children with sickle cell disease: what comes next?
Ohene-Frempong K; Smith-Whitley K
Semin Hematol; 1997 Jul; 34(3 Suppl 3):30-41. PubMed ID: 9317199
[TBL] [Abstract][Full Text] [Related]
36. Hydroxyurea-induced hematological response in transfusion-independent beta-thalassemia intermedia: case series and review of literature.
Ehsani MA; Hedayati-Asl AA; Bagheri A; Zeinali S; Rashidi A
Pediatr Hematol Oncol; 2009 Nov; 26(8):560-5. PubMed ID: 19954365
[TBL] [Abstract][Full Text] [Related]
37. Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia.
Koren A; Segal-Kupershmit D; Zalman L; Levin C; Abu Hana M; Palmor H; Luder A; Attias D
Pediatr Hematol Oncol; 1999; 16(3):221-32. PubMed ID: 10326220
[TBL] [Abstract][Full Text] [Related]
38. Effects of hydroxyurea treatment on cerebral oxygenation in adult patients with sickle cell disease: an open-label pilot study.
Tavakkoli F; Nahavandi M; Wyche MQ; Castro O
Clin Ther; 2005 Jul; 27(7):1083-8. PubMed ID: 16154487
[TBL] [Abstract][Full Text] [Related]
39. Exposure to hydroxyurea during pregnancy in sickle-beta thalassemia: a report of 2 cases.
Italia KY; Jijina FF; Chandrakala S; Nadkarni AH; Sawant P; Ghosh K; Colah RB
J Clin Pharmacol; 2010 Feb; 50(2):231-4. PubMed ID: 19797538
[No Abstract] [Full Text] [Related]
40. Altered levels of pro-inflammatory cytokines in sickle cell disease patients during vaso-occlusive crises and the steady state condition.
Keikhaei B; Mohseni AR; Norouzirad R; Alinejadi M; Ghanbari S; Shiravi F; Solgi G
Eur Cytokine Netw; 2013 Mar; 24(1):45-52. PubMed ID: 23608554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
